Side-by-side comparison of AI visibility scores, market position, and capabilities
New York City global commercial P&C insurer (NYSE: AIG) ~$27B FY2024 revenue; post-2008 bailout transformation complete, Corebridge life insurance spinoff, specialty lines focus competing with Chubb and Zurich.
American International Group, Inc. (AIG) is a New York City-based global commercial property-casualty insurance company — publicly traded on the New York Stock Exchange (NYSE: AIG) as an S&P 500 Financials component — providing commercial insurance (property, casualty, financial lines, specialty), personal insurance, and reinsurance to businesses, organizations, and individuals in 200+ countries through approximately 26,000 employees. AIG has completed a decade-long strategic transformation from the systemically important financial institution (SIFI) that required a $185 billion US government bailout during the 2008 financial crisis — divesting life insurance (AIG Life and Retirement separated as Corebridge Financial, NYSE: CRBG, with AIG owning 48% stake following Corebridge's 2022 IPO and ongoing stake sales), non-core property assets, and non-insurance financial businesses — focusing the company exclusively on global commercial and specialty P&C insurance. In fiscal year 2024, AIG reported revenues of approximately $27 billion with adjusted after-tax income growing as underwriting profitability improved following the combined ratio improvement initiatives. CEO Peter Zaffino has repositioned AIG as a "best-in-class" global commercial insurer: achieving combined ratio below 90% in its General Insurance segment, expanding the portfolio toward specialty lines (financial lines — D&O, E&O, cyber insurance; marine and energy insurance; aerospace) with superior pricing power versus commodity commercial P&C. AIG's complete exit from the low-margin high-volatility consumer auto and homeowners insurance markets (sold to Safeco/Liberty Mutual, Assurant partnerships) refocuses underwriting capacity toward commercial and specialty lines with better long-term profitability.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.